Neal Meropol Profile
Neal Meropol

@NealMeropol

Followers
153
Following
59
Media
0
Statuses
51

Joined November 2017
Don't wanna be here? Send us removal request.
@NealMeropol
Neal Meropol
1 year
Clinical trials need to be representative if we expect the results to be applicable to ALL cancer patients. Let's double down to help address this imperative by carefully designing trials that optimize patient access!
@flatironhealth
Flatiron Health
1 year
“It’s really a crisis. And it’s a societal imperative, in my opinion, to fix this problem of #clinicaltrial representativeness.” Building off an article in @NEJMEvidence, data has the ability to transform trials, improve outcomes, & address disparities. https://t.co/5fAMpAqgR7
0
0
4
@NealMeropol
Neal Meropol
1 year
Many thanks to Daniel Levine on The Bio Report for a great conversation about the many ways that #realworlddata can support evidence generation to benefit cancer patients.
@flatironhealth
Flatiron Health
1 year
Neal Meropol, Head of Research Oncology, was recently interviewed on The Bio Report podcast to explain how #realworlddata from the EHR is transforming cancer #clinicaltrials and drug development. Tune in:
0
0
2
@flatironhealth
Flatiron Health
1 year
Neal Meropol, Head of Research Oncology, was recently interviewed on The Bio Report podcast to explain how #realworlddata from the EHR is transforming cancer #clinicaltrials and drug development. Tune in:
0
1
1
@flatironhealth
Flatiron Health
2 years
ANNOUNCED TODAY: Flatiron is expanding their collaboration with @NCCN to further enable research with #RWD, create meaningful impact on cancer care, & allow cancer centers access to data sets to evaluate & enhance the quality of care given at their sites. https://t.co/ER0kad9kOL
Tweet card summary image
resources.flatiron.com
Flatiron Health today announced the renewal of their collaboration with the National Comprehensive Cancer Network® (NCCN®).
1
1
6
@flatironhealth
Flatiron Health
2 years
#NewResearch published today in @NEJMEvidence, investigates how #RWD use to optimize and broaden inclusion criteria impacts the diversity of eligible patients with cancer. Hear from Maneet Kaur about the study's inspiration and explore the full pub: https://t.co/jesMNhJmtQ
1
1
0
@flatironhealth
Flatiron Health
3 years
#Clinicalresearch data collection & transfer methods have not significantly advanced over the last 50 years. A new paper by @flatironhealth & @FierceBiotech proposes ways that the EHR can accelerate #clinicaltrials to benefit patients, sites, & sponsors
1
3
4
@NealMeropol
Neal Meropol
3 years
Moving clinical trial data collection into the 21st century.
@flatironhealth
Flatiron Health
3 years
Technology has the power to support changes needed to reduce #clinicalresearch site burden, especially related to data collection. https://t.co/Uk8LZO0yO7 Connect with our team to discuss how our EHR-to-EDC tech is changing the future of clinical research
0
0
3
@RueschCenter
Cure GI Cancers
3 years
Register today for the #RueschSymposium keynote with @NealMeropol of @flatironhealth on Friday, November 18th at 12PM ET. Join us in person or virtually using promo code Guest2022. https://t.co/cflynvxmE1. @LombardiCancer @MedStarGUH @OncLive
1
8
8
@flatironhealth
Flatiron Health
3 years
@FlatironHealth’s @NealMeropol spoke w/@TheCancerLetter on @theNCI CTAC proposed guidelines for streamlining data collection requirements for clinical trials. Neal, Co-Chair of the NCI’s Working Group on Streamlining Clinical Trials, shared his thoughts: https://t.co/ANsLvVL0Pp
1
1
0
@RueschCenter
Cure GI Cancers
3 years
Join leading GI Cancer experts at the 13th Annual Ruesch Center Symposium on November 18th and 19th. Learn more about the agenda and speakers for Friday, November 18th. Use promo code Guest2022 to register. https://t.co/cflynvxUtz @LombardiCancer @MedStarGUH
0
5
11
@NealMeropol
Neal Meropol
3 years
@DrSGraff Chock full of important insights!
0
1
1
@flatironhealth
Flatiron Health
3 years
Ariel Bourla sat down w/ @JournPrecMed to discuss a study done in partnership w/@FoundationATCG & @Genentech, that found potential for an add'l diagnostic approach to personalized NSCLC therapy. More on the thought & design behind this innovative study.
0
3
3
@LGM_Biostats
Liz Garrett-Mayer, PhD
3 years
@NealMeropol from @flatironhealth talking about the power of technology to make it easier for all of us to participate in research at #ASCO22. 70% of info needed for clinical trial data is already in EHRs. Reduce costs & increase evidence generation by leveraging the EHR!
0
3
6
@AnjeeDavis
AnjeeDavis
4 years
Our Path to a Cure Video is the bomb!!! Love our research champions!!! Starring @CathyEngMD @skopetz @NealMeropol @Winni195 @FightCRC @VUMChealth @flatironhealth @MDAndersonNews @ChrisHeery We are ready to fight for a cure! 💙💪🏽👏🏼 https://t.co/aeZbfbFe1j
0
6
16
@NealMeropol
Neal Meropol
4 years
Check out this publication from the @NASEM_Health National Cancer Policy Forum! Opportunities and Challenges for Using Digital Health Applications in Oncology - Proceedings of a Workshop. Read now: https://t.co/6ybFkTdg7M #natlcancerforum
0
0
1
@flatironhealth
Flatiron Health
4 years
We learned Medicaid expansion reduced racial disparities in treatment of patients with cancer. Full methods and results now available via @AJMC_Journal. Another illustration of our commitment to #inclusive research & health equity @cpgYALE @DrBlytheAdamson https://t.co/oUILpDiPKw
0
5
16
@NealMeropol
Neal Meropol
4 years
I had the privilege to highlight the great potential of applying #AI to #EHR-derived data to advance cancer research and clinical care. Read our commentary here:
0
2
4
@flatironhealth
Flatiron Health
4 years
Our #ASCO21 research demonstrates the latest applications of EHR-derived #RWD to advance #cancer care. Learn more about this research from the authors. https://t.co/Fv4tVNmcOT We are also proud to see Flatiron data utilized in more than 40 other ASCO abstracts.
0
4
6
@flatironhealth
Flatiron Health
4 years
We're proud to join @aetioninc, @IQVIA_global, @Syapse and @TempusLabs in announcing the formation of the #RWEAlliance to advance the use of real-world evidence to support regulatory decisions and benefit patients. Learn more: https://t.co/uSn8J2B3je
0
7
24
@flatironhealth
Flatiron Health
5 years
Proud to have contributed to this important work
@PC3Innovation
Penn Cancer Innovation
5 years
Out NOW @JAMAOnc: NSCLC patients w/PD-L1 of 50%+ & KRAS mutation lived longer when treated w/immunotherapy alone in analysis of @flatironhealth data by PC3I's @Ron_cology + @CharuAggarwalMD @LovaSunMD @CoreyLangerMD & team. #lungcancer #RWE #cancercare https://t.co/1ERQsdGbR1
0
4
7